APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Group A and C Conjugate Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Meningococcal Group A and C Conjugate Vaccine Market Analysis and Forecast 2026-2032

29 December 2025197 pages

Choose your research edition.

Industry ResearchMeningococcal Group A and C Conjugate Vaccine Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Group A and C Conjugate Vaccine Industry Growth and Trends Forecast to 203273 pages · $3,450 USDMarket StructureGlobal Meningococcal Group A and C Conjugate Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Group A and C Conjugate Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Group A and C Conjugate Vaccine Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Meningococcal Group A and C Conjugate Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Meningococcal Group A and C Conjugate Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Meningococcal Group A and C Conjugate Vaccine include GSK, Pfizer, Sanofi Pasteur and Chongqing Zhifei Biological Products, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Meningococcal Group A and C Conjugate Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Meningococcal Group A and C Conjugate Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Meningococcal Group A and C Conjugate Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Group A and C Conjugate Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Meningococcal Group A and C Conjugate Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Meningococcal Group A and C Conjugate Vaccine sales, projected growth trends, production technology, application and end-user industry.

Meningococcal Group A and C Conjugate Vaccine Segment by Company

GSK

Pfizer

Sanofi Pasteur

Chongqing Zhifei Biological Products

Meningococcal Group A and C Conjugate Vaccine Segment by Type

Prefilled

Non-prefilled

Meningococcal Group A and C Conjugate Vaccine Segment by Application

Adults

Children

Meningococcal Group A and C Conjugate Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Group A and C Conjugate Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Group A and C Conjugate Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Group A and C Conjugate Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Meningococcal Group A and C Conjugate Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Meningococcal Group A and C Conjugate Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Group A and C Conjugate Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Prefilled Major Manufacturers Table 3. Non-prefilled Major Manufacturers Table 4. Global Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Adults Major Manufacturers Table 6. Children Major Manufacturers Table 7. Meningococcal Group A and C Conjugate Vaccine Industry Trends Table 8. Meningococcal Group A and C Conjugate Vaccine Industry Drivers Table 9. Meningococcal Group A and C Conjugate Vaccine Industry Opportunities and Challenges Table 10. Meningococcal Group A and C Conjugate Vaccine Industry Restraints Table 11. Global Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 12. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 13. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 14. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021-2026) Table 15. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2027-2032) Table 16. Global Meningococcal Group A and C Conjugate Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 17. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021-2026) & (K Units) Table 18. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2027-2032) & (K Units) Table 19. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021-2026) Table 20. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2027-2032) Table 21. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 22. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 23. Global Meningococcal Group A and C Conjugate Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 24. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Manufacturers (2021-2026) Table 25. Global Meningococcal Group A and C Conjugate Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 26. Global Meningococcal Group A and C Conjugate Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 27. Global Meningococcal Group A and C Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 28. Global Meningococcal Group A and C Conjugate Vaccine Manufacturers, Product Type & Application Table 29. Global Meningococcal Group A and C Conjugate Vaccine Manufacturers' Establishment Date Table 30. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 31. Global Meningococcal Group A and C Conjugate Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 32. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 34. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 35. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021-2026) Table 36. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2027-2032) Table 37. Global Meningococcal Group A and C Conjugate Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 38. Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 39. Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 40. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2026) Table 41. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2027-2032) Table 42. Global Meningococcal Group A and C Conjugate Vaccine Price by Type (2021-2026) & (US$/Unit) Table 43. Global Meningococcal Group A and C Conjugate Vaccine Price by Type (2027-2032) & (US$/Unit) Table 44. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 45. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 46. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 47. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021-2026) Table 48. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2027-2032) Table 49. Global Meningococcal Group A and C Conjugate Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 50. Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 51. Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 52. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2026) Table 53. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2027-2032) Table 54. Global Meningococcal Group A and C Conjugate Vaccine Price by Application (2021-2026) & (US$/Unit) Table 55. Global Meningococcal Group A and C Conjugate Vaccine Price by Application (2027-2032) & (US$/Unit) Table 56. GSK Company Information Table 57. GSK Business Overview Table 58. GSK Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 59. GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 60. GSK Recent Development Table 61. Pfizer Company Information Table 62. Pfizer Business Overview Table 63. Pfizer Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 65. Pfizer Recent Development Table 66. Sanofi Pasteur Company Information Table 67. Sanofi Pasteur Business Overview Table 68. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 70. Sanofi Pasteur Recent Development Table 71. Chongqing Zhifei Biological Products Company Information Table 72. Chongqing Zhifei Biological Products Business Overview Table 73. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio Table 75. Chongqing Zhifei Biological Products Recent Development Table 76. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 79. North America Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 80. North America Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 81. North America Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 82. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 83. North America Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 84. North America Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 85. North America Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 86. North America Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 87. North America Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 88. North America Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 89. North America Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 90. North America Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 91. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 92. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 93. North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 94. North America Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 95. North America Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 96. United States Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 97. Canada Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 98. Mexico Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 99. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 100. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 101. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 102. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 103. Europe Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 104. Europe Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 105. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 106. Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 107. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 108. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 109. Europe Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 110. Europe Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 111. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 112. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 113. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 114. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 115. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 116. Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 117. Europe Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 118. Europe Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 119. Germany Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 120. France Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 121. U.K. Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 122. Italy Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 123. Russia Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 124. Spain Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 125. Netherlands Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 126. Switzerland Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 127. Sweden Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 128. Poland Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 129. China Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 130. China Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 131. China Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 132. China Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 133. China Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 134. China Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 135. China Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 136. China Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 137. China Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 138. China Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 139. China Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 140. China Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 141. Asia Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 142. Asia Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 143. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 144. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 145. Asia Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 146. Asia Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 147. Asia Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 148. Asia Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 149. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 150. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 151. Asia Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 152. Asia Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 153. Asia Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 154. Asia Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 155. Asia Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 156. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 157. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 158. Asia Meningococcal Group A and C Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 159. Asia Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 160. Asia Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 161. Japan Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 162. South Korea Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 163. India Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 164. Australia Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 165. Taiwan Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 166. Southeast Asia Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 167. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 168. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 169. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2026) & (K Units) Table 170. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Type (2027-2032) & (K Units) Table 171. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 172. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 173. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 174. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 175. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2026) & (K Units) Table 176. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Application (2027-2032) & (K Units) Table 177. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 178. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 179. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 183. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021-2026) & (K Units) Table 184. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Country (2027-2032) & (K Units) Table 185. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 186. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 187. Brazil Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 188. Argentina Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 189. Chile Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 190. Colombia Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 191. Peru Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 192. Saudi Arabia Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 193. Israel Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 194. UAE Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 195. Turkey Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 196. Iran Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 197. Egypt Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Table 198. Key Raw Materials Table 199. Raw Materials Key Suppliers Table 200. Meningococcal Group A and C Conjugate Vaccine Distributors List Table 201. Meningococcal Group A and C Conjugate Vaccine Customers List Table 202. Research Programs/Design for This Report Table 203. Authors List of This Report Table 204. Secondary Sources Table 205. Primary Sources List of Figures Figure 1. Meningococcal Group A and C Conjugate Vaccine Image Figure 2. Global Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Group A and C Conjugate Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Prefilled Image Figure 5. Non-prefilled Image Figure 6. Global Meningococcal Group A and C Conjugate Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Meningococcal Group A and C Conjugate Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Adults Image Figure 9. Children Image Figure 10. Global Meningococcal Group A and C Conjugate Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Meningococcal Group A and C Conjugate Vaccine Revenue (2021-2032) & (US$ Million) Figure 12. Global Meningococcal Group A and C Conjugate Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 13. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 14. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021-2032) Figure 15. Global Meningococcal Group A and C Conjugate Vaccine Sales (2021-2032) & (K Units) Figure 16. Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 17. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021-2032) Figure 18. US & Canada & Mexico Meningococcal Group A and C Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 19. Europe Meningococcal Group A and C Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 20. China Meningococcal Group A and C Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. Asia (Excluding China) Meningococcal Group A and C Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. South America, Middle East and Africa Meningococcal Group A and C Conjugate Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. Global Meningococcal Group A and C Conjugate Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 24. Global Meningococcal Group A and C Conjugate Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 25. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 26. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 27. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 28. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021-2032) Figure 29. Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 30. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2032) Figure 32. Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 33. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 34. Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021-2032) Figure 35. Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 36. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2032) Figure 38. North America Meningococcal Group A and C Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 39. North America Meningococcal Group A and C Conjugate Vaccine Sales Share by Type (2021-2032) Figure 40. North America Meningococcal Group A and C Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 41. North America Meningococcal Group A and C Conjugate Vaccine Sales Share by Application (2021-2032) Figure 42. North America Meningococcal Group A and C Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 43. North America Meningococcal Group A and C Conjugate Vaccine Sales Share by Country (2021-2032) Figure 44. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 45. Europe Meningococcal Group A and C Conjugate Vaccine Sales Share by Type (2021-2032) Figure 46. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 47. Europe Meningococcal Group A and C Conjugate Vaccine Sales Share by Application (2021-2032) Figure 48. Europe Meningococcal Group A and C Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 49. Europe Meningococcal Group A and C Conjugate Vaccine Sales Share by Country (2021-2032) Figure 50. China Meningococcal Group A and C Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 51. China Meningococcal Group A and C Conjugate Vaccine Sales Share by Type (2021-2032) Figure 52. China Meningococcal Group A and C Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 53. China Meningococcal Group A and C Conjugate Vaccine Sales Share by Application (2021-2032) Figure 54. Asia Meningococcal Group A and C Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 55. Asia Meningococcal Group A and C Conjugate Vaccine Sales Share by Type (2021-2032) Figure 56. Asia Meningococcal Group A and C Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 57. Asia Meningococcal Group A and C Conjugate Vaccine Sales Share by Application (2021-2032) Figure 58. Asia Meningococcal Group A and C Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 59. Asia Meningococcal Group A and C Conjugate Vaccine Sales Share by Country (2021-2032) Figure 60. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Share by Type (2021-2032) Figure 61. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Share by Type (2021-2032) Figure 62. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Share by Application (2021-2032) Figure 63. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Share by Application (2021-2032) Figure 64. SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Share by Country (2021-2032) Figure 65. SAMEA Meningococcal Group A and C Conjugate Vaccine Sales Share by Country (2021-2032) Figure 66. Meningococcal Group A and C Conjugate Vaccine Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Meningococcal Group A and C Conjugate Vaccine Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Prefilled
  • Non-prefilled
Applications
  • Adults
  • Children
Companies covered
  • GSK
  • Pfizer
  • Sanofi Pasteur
  • Chongqing Zhifei Biological Products

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Meningococcal Group A and C Conjugate Vaccine Market by Type
  3. 1.2.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Prefilled
  5. 1.2.3 Non-prefilled
  6. 1.3 Meningococcal Group A and C Conjugate Vaccine Market by Application
  7. 1.3.1 Global Meningococcal Group A and C Conjugate Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Adults
  9. 1.3.3 Children
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 Meningococcal Group A and C Conjugate Vaccine Market Dynamics
  1. 2.1 Meningococcal Group A and C Conjugate Vaccine Industry Trends
  2. 2.2 Meningococcal Group A and C Conjugate Vaccine Industry Drivers
  3. 2.3 Meningococcal Group A and C Conjugate Vaccine Industry Opportunities and Challenges
  4. 2.4 Meningococcal Group A and C Conjugate Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region
  3. 3.2.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region
  9. 3.4.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Meningococcal Group A and C Conjugate Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Meningococcal Group A and C Conjugate Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Manufacturers
  6. 4.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Meningococcal Group A and C Conjugate Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Meningococcal Group A and C Conjugate Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Meningococcal Group A and C Conjugate Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Meningococcal Group A and C Conjugate Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Meningococcal Group A and C Conjugate Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Meningococcal Group A and C Conjugate Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Meningococcal Group A and C Conjugate Vaccine Tier 1, Tier 2, and Tier 3
5 Meningococcal Group A and C Conjugate Vaccine Market by Type
  1. 5.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type
  2. 5.1.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type
  6. 5.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Meningococcal Group A and C Conjugate Vaccine Price by Type
6 Meningococcal Group A and C Conjugate Vaccine Market by Application
  1. 6.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application
  2. 6.1.1 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Meningococcal Group A and C Conjugate Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application
  6. 6.2.1 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Meningococcal Group A and C Conjugate Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Meningococcal Group A and C Conjugate Vaccine Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Pfizer
  8. 7.2.1 Pfizer Company Information
  9. 7.2.2 Pfizer Business Overview
  10. 7.2.3 Pfizer Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Pfizer Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  12. 7.2.5 Pfizer Recent Developments
  13. 7.3 Sanofi Pasteur
  14. 7.3.1 Sanofi Pasteur Company Information
  15. 7.3.2 Sanofi Pasteur Business Overview
  16. 7.3.3 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Pasteur Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  18. 7.3.5 Sanofi Pasteur Recent Developments
  19. 7.4 Chongqing Zhifei Biological Products
  20. 7.4.1 Chongqing Zhifei Biological Products Company Information
  21. 7.4.2 Chongqing Zhifei Biological Products Business Overview
  22. 7.4.3 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Chongqing Zhifei Biological Products Meningococcal Group A and C Conjugate Vaccine Product Portfolio
  24. 7.4.5 Chongqing Zhifei Biological Products Recent Developments
8 North America
  1. 8.1 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Type
  2. 8.1.1 North America Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Meningococcal Group A and C Conjugate Vaccine Price by Type (2021-2032)
  5. 8.2 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Application
  6. 8.2.1 North America Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Meningococcal Group A and C Conjugate Vaccine Price by Application (2021-2032)
  9. 8.3 North America Meningococcal Group A and C Conjugate Vaccine Market Size by Country
  10. 8.3.1 North America Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Meningococcal Group A and C Conjugate Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Type
  2. 9.1.1 Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Meningococcal Group A and C Conjugate Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Application
  6. 9.2.1 Europe Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Meningococcal Group A and C Conjugate Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Meningococcal Group A and C Conjugate Vaccine Market Size by Country
  10. 9.3.1 Europe Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Meningococcal Group A and C Conjugate Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Meningococcal Group A and C Conjugate Vaccine Market Size by Type
  2. 10.1.1 China Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Meningococcal Group A and C Conjugate Vaccine Price by Type (2021-2032)
  5. 10.2 China Meningococcal Group A and C Conjugate Vaccine Market Size by Application
  6. 10.2.1 China Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Meningococcal Group A and C Conjugate Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Meningococcal Group A and C Conjugate Vaccine Market Size by Type
  2. 11.1.1 Asia Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Meningococcal Group A and C Conjugate Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Meningococcal Group A and C Conjugate Vaccine Market Size by Application
  6. 11.2.1 Asia Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Meningococcal Group A and C Conjugate Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Meningococcal Group A and C Conjugate Vaccine Market Size by Country
  10. 11.3.1 Asia Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Meningococcal Group A and C Conjugate Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Meningococcal Group A and C Conjugate Vaccine Market Size by Type
  2. 12.1.1 SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Meningococcal Group A and C Conjugate Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Meningococcal Group A and C Conjugate Vaccine Market Size by Application
  6. 12.2.1 SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Meningococcal Group A and C Conjugate Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Meningococcal Group A and C Conjugate Vaccine Market Size by Country
  10. 12.3.1 SAMEA Meningococcal Group A and C Conjugate Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Meningococcal Group A and C Conjugate Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Meningococcal Group A and C Conjugate Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Meningococcal Group A and C Conjugate Vaccine Value Chain Analysis
  2. 13.1.1 Meningococcal Group A and C Conjugate Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Meningococcal Group A and C Conjugate Vaccine Production Mode & Process
  6. 13.2 Meningococcal Group A and C Conjugate Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Meningococcal Group A and C Conjugate Vaccine Distributors
  9. 13.2.3 Meningococcal Group A and C Conjugate Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst